Alkeran is a chemotherapeutic drug used in the treatment of conditions such as multiple myeloma, ovarian cancer, AL amyloidosis and retinoblastoma. The active pharmaceutical ingredient of the medicine is melphalan. Belonging to a class of drugs known as alkylating agents, Alkeran works by interfering in the DNA replication process of cancerous cells, thereby destroying them. Alkeran is typically administered by intravenous infusion over 20 minutes every couple of weeks, depending on the regimen chosen by the oncologist. Side-effects include immunosuppression, which may lead to an increased risk of infection and bleeding.